ClinicalTrials.gg
Status unknownNCT03385200Updated Dec 28, 2017

KVUS at Neoadjuvant CTx of Breast Cancer

A Phase 3 interventional study of SonoVue in Early Primary Breast Cancer, sponsored by RWTH Aachen University. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-28.

Sponsored by RWTH Aachen University · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Dec 2016, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Planned enrollment
480th of 580
60 · median 273
Started
2016
with 23 others
Phase 3
222 of 678
29 open now
Registered
407th of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 480th largest by planned enrollment of the 580 interventional ones that give a count, is one of 24 that started in 2016, is one of 222 in phase 3, and was the 407th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Effect of the contrast-enhanced diagnostic ultrasound during neoadjuvant chemotherapy of breast cancer on the achieved tumor size reduction and tolerability of chemotherapy

Read the detailed description

The 5-year survival rate of breast cancer patients is decreasing in the advanced, metastatic stage from 99% to 26%. Therefore an optimization of the therapy of advanced breast cancer is urgently needed.

To increase the echogenicity of the blood in the ultrasound, microbubbles were developed working as stable, biocompatible contrast agent in ultrasound. Such a clinically approved ultrasound contrast agent is SonoVue® (Bracco International B.V., Amsterdam). SonoVue® is approved by the European Medicines Agency (EMA) (approval number EU/1/01/177/002) for the visualization of focal vascularization lesions of the liver and breast within Doppler sonography and is applied in breast cancer patients primarily for the purpose of diagnosis as well as to evaluate the response to the neoadjuvant used chemotherapy.

Animal studies using the contrast enhanced ultrasound have shown that the administration of this contrast agent increases the penetration and accumulation of drugs in the tumor as well as the permeability of the blood-brain barrier resulting in a precise and effective drug distribution. In the tumor animal model it could be shown that a combined treatment with chemotherapy and contrast enhanced ultrasound results in a decreased tumor growth and a prolonged survival. Patients with inoperable pancreatic cancer showed a reduced tumor growth and better tolerability of chemotherapy when administrating the contrast enhanced diagnostic ultrasound during palliative chemotherapy. This could be due to the better tumor response, but also due to the more targeted chemotherapy distribution.

The purpose of this study is to examine whether the use of the contrast enhanced diagnostic ultrasound during neoadjuvant chemotherapy results in an increased tumor regression in comparison to native ultrasound. It is an Investigator Initiated Trial and is funded by internal means.

03

Conditions studied

  • Early Primary Breast Cancer

Browse trials for

Keywords

  • breast cancer, neoadjuvant chemotherapy, ultrasound, microbubbles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • written
  • age > 18 yrs
  • confirmed primary breast cancer including all intrinsic subtypes
  • treatment with chemotherapy
  • persons who are legally competent and mentally able to follow the instructions of the study team

Exclusion criteria

Exclusion Criteria:

  • / allergy to sulfur hexafluoride, Macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol-sodium, palmitic acid
  • right-left shunt,
  • severe pulmonary hypertension (pulmonary arterial pressure > 90 mmHg)
  • uncontrolled systemic hypertension
  • acute respiratory distress syndrome
  • pregnancy
  • commitment of the patient to any resident institution by order of any court or authority
  • expectation of missing compliance
  • alcohol or drug abuse
  • patients who are in a relationship of dependence or in a working relationship to the sponsor, the investigator or his representative
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    A

    Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound

    Drug: SonoVue

  • No intervention
    B

    Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound

Interventions

06

What researchers measure

Primary outcomes

  1. Tumor size reduction (1)

    pCR (pathohistological complete remission)

    Time frame: 18 / 24 weeks

  2. Tumor size reduction (2)

    cCR (clinical complete remission)

    Time frame: 18 / 24 weeks

  3. Tumor size reduction (3)

    measured by ultrasound (% reduction in therapy)

    Time frame: 18 / 24 weeks

Secondary outcomes

  1. proliferation rate of the tumor cells

    Ki67 protein analysis

    Time frame: 18 / 24 weeks

  2. narrowing the invasion front of the tumors

    ultrasound

    Time frame: 18 / 24 weeks

  3. macrophage density in the tumor

    serum chemistry

    Time frame: 18 / 24 weeks

  4. vascularization of the tumor

    ultrasound

    Time frame: 18 / 24 weeks

  5. tolerability of chemotherapy

    % reduction in therapy

    Time frame: 18 / 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Gynecology and Obstetrics
    Aachen, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The study results will be published in at least one scientific article.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Jun 2019, 30 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 30 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2017
First posted
Dec 28, 2017
StartActual
Dec 12, 2016
Primary completionEst.
Jun 12, 2019
CompletionEst.
Dec 12, 2019
Last update
Dec 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03385200
Collaborators
Univ.-Prof. Dr. med. F. Kiessling
Responsible party
Elmar Stickeler (Univ.-Prof. Dr. med., RWTH Aachen University) — Principal investigator
First posted
Dec 28, 2017
Start date
Dec 12, 2016
Primary completion
Jun 12, 2019 (estimated)
Completion
Dec 12, 2019 (estimated)
Last update
Dec 28, 2017

Study contacts

Elmar Stickeler, Univ.-Prof. Dr. med.
Contact
estickeler@ukaachen.de
+49 241 80 88400
Fabian Kiessling, Univ.-Prof. Dr. med.
Contact
fkiessling@ukaachen.de
+49 241 80 80116
Elmar Stickeler, niv.-Prof. Dr. med.
principal investigator · Department of Gynecology and Obstetrics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Contrast agent BR1

Start the discussion